English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

1 Associate Professor, Department of General Medicine, Hi-tech Medical College and Hospital Bhubaneswar-751025 Odisha, India 2 Professor, Dept of Pulmonary Medicine, Hi-tech Medical College and Hospital, Bhubaneswar-751025 Odisha India 3 Research Associate, Hi-tech Medical College and Hospital, Bhubaneswar-751025 Odisha, India *Corresponding Author Dr Sanjay Kumar Jangid Associate Professor, Department of General Medicine, Hi-tech Medical College and Hospital Bhubaneswar-751025 Odisha, India Email: drsanjay_jangid@yahoo.co.in, Mobile: 9337671521 Summary This 12-week study compared the efficacy and safety of a fixed combination of fluticasone propionate plus formoterol (FL/F) 250/12 μgb.i.d. administered via a dry powder inhaler (DPI) to a combination of budesonide plus formoterol (BD/F) 400/12 μgb.i.d. After a 2-week run-in period (in which all patients were treated exclusively with budesonide plus formoterol), patients aged 12–65 years of age (N = 98) with uncontrolled asthma were randomized into an actively controlled, open-labelled, parallel-group study. The primary objective was to demonstrate non-inferiority, measured by morning peak expiratory flow (mPEF). The non-inferiority was demonstrated. A statistically significant improvement from baseline was observed in both groups in terms of lung function, asthma control, and the use of rescue medication. FL/F demonstrated a statistical superiority to BD/F in terms of lung function (FEV1) (p = 0.01) and for asthma control (p = 0.02). Non-significant between-group differences were observed with regards to exacerbation rates and adverse events. In uncontrolled or partly controlled asthma patients, the use of a combination of fluticasone propionate plus formoterol via DPI for 12-weeks was non-inferior and showed improvements in FEV1 and asthma control when compared to a combination of budesonide plus formoterol.

Fluticasone/Formoterol dry powder versus Budesonide/Formoterol in adults and adolescents with uncontrolled or partly controlled asthma